Charles River Laboratories International Inc

Charles River Laboratories International, Inc. is an early-stage contract research company that operates worldwide. The company's services include basic research, discovery, clinical support, safety and efficacy, and manufacturing. Founded in 1947, Charles River Laboratories has its headquarters in Wilmington, Massachusetts. The company operates through two segments: Discovery and Safety Assessment (DSA) and Manufacturing Solutions (Manufacturing). The company's DSA segment handles the services necessary to take a drug through the early development process, while the Manufacturing segment handles Biologics Solutions, Microbial Solutions and Avian Vaccine Services. The company's clients include pharmaceutical, biotechnology, agrochemical, government, and academic organisations. Charles River Laboratories stock is listed on the NYSE under the ticker CRL. In January 2021, Charles River Laboratories acquired Distribute Bio, the producers of a platform for therapeutic antibody discovery and optimisation. In March 2021, the company announced the acquisition of Cognate BioServices in a deal worth approximately $875m. Cognate BioServices is a cell and gene therapy contract development and manufacturing organisation. In the same month, Charles River Laboratories completed its acquisition of Retrogenix Limited, another early-stage contract research organisation. The purchase price for this acquisition was an estimated $48m, with an additional potential $7m being paid based on performance. Learn more about the share price performance of CRL on eToro.